SI-BONE to participate in 24th Annual Needham Virtual Growth Conference

Rhea-AI Summary

SI-BONE, a leader in surgical treatments for musculoskeletal disorders, announced participation in the 24th Annual Needham Virtual Growth Conference on January 12, 2022, at 5:00 p.m. ET. The conference highlights the company’s innovative iFuse Implant System, which addresses SI joint pain affecting 15%-30% of chronic low back pain patients. With over 60,000 procedures performed by more than 2,500 surgeons, the iFuse system is supported by significant clinical evidence and insurance coverage. For more information, visit www.si-bone.com.

SANTA CLARA, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced management is scheduled to participate in the following investor conference:

24^th Annual Needham Virtual Growth Conference on Wednesday, January 12, 2022 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.

Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.si-bone.com.

About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. In 2009, SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, shown to be a source of pain in 15% to 30% of people with chronic low back pain. Since then, more than 2,500 surgeons have performed a combined total of more than 60,000 SI joint fusion procedures. A unique body of evidence supports the iFuse Implant System, including two RCT’s and over 100 peer reviewed publications that has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with iFuse Triangular Implants. SI-BONE is leveraging its market leadership position in the surgical treatment of SI joint disorders, supported by this proprietary reimbursement advantage, to commercialize other devices intended for surgical treatment of related conditions of the human anatomy. For more information or to join our team, please visit us at www.si-bone.com. 

For additional information about the company or products, including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved.

Investor Contact:
Matt Bacso, CFA
investors@si-bone.com

FAQ

When is SI-BONE participating in the investor conference?

SI-BONE will participate in the 24th Annual Needham Virtual Growth Conference on January 12, 2022, at 5:00 p.m. ET.

What is the iFuse Implant System by SI-BONE?

The iFuse Implant System is designed for minimally invasive surgery of the sacroiliac joint, addressing pain in chronic low back pain patients.

How many procedures have been performed using the iFuse Implant System?

More than 60,000 SI joint fusion procedures have been performed using the iFuse Implant System by over 2,500 surgeons.

What evidence supports the iFuse Implant System?

The iFuse Implant System is supported by two randomized controlled trials and over 100 peer-reviewed publications.

Where can I find more information about SI-BONE?

More information about SI-BONE and its products can be found on their website at www.si-bone.com.